^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CDH1 expression

i
Other names: CDH1, CD324, UVO, uvomorulin, Cadherin 1, type 1, E-cadherin
Entrez ID:
Related biomarkers:
3d
miRNA‑22‑3p inhibits cell viability and metastasis of nasopharyngeal carcinoma by targeting FOXP1. (PubMed, Oncol Lett)
Notably, FOXP1 overexpression counteracted the suppressive effects induced by transfection with miRNA-22-3p mimic on HK-1 cell viability and migration. Therefore, these data indicate that miRNA-22-3p may be a clinically valuable biomarker for the therapy of NPC.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • FOXP1 (Forkhead Box P1) • CDH2 (Cadherin 2)
|
CDH1 expression • VIM expression • FOXP1 overexpression
3d
PF4 Silencing Promotes Trophoblast Cell Proliferation, Migration, Invasion and EMT by Regulating SOCS3/STAT3 Signaling Pathway. (PubMed, Endocr Metab Immune Disord Drug Targets)
In summary, PF4 participated in the proliferation, migration, invasion, EMT and angiogenesis of trophoblast cells by modulating the SOCS3/STAT3 signaling pathway, indicating that targeting the PF4/SOCS3/STAT3 pathway could be a novel therapy for RM.
Journal
|
CDH1 (Cadherin 1) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • SOCS3 (Suppressor Of Cytokine Signaling 3)
|
CDH1 expression
3d
PTEN inhibits epithelial mesenchymal transition of thyroid cancer cells by regulating the Wnt/β-Catenin signaling pathway. (PubMed, Discov Oncol)
PTEN functions to inhibit EMT and the invasive and migratory characteristics of THCA cells by blocking the activation of the Wnt/β-catenin pathway.
Journal
|
PTEN (Phosphatase and tensin homolog) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2)
|
PTEN expression • CDH1 expression • VIM expression
4d
Antitumor Activity of Selenopsammaplin A Analog (SPA-10091-HCl) via Histone Methyltransferase DOT1L Degradation and Apoptosis Induction in Castration-Resistant Prostate Cancer Cells. (PubMed, Eur J Pharm Sci)
Moreover, SPA-10091-HCl effectively inhibited tumor growth in the PC3 cells-implanted xenograft mouse model without any overt toxicity. These results indicate SPA-10091-HCl as a potential candidate for further development as a chemotherapeutic agent against CRPC.
Journal • PARP Biomarker • IO biomarker • Epigenetic controller
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • CASP3 (Caspase 3) • VIM (Vimentin) • CASP9 (Caspase 9) • CDH2 (Cadherin 2) • DOT1L (DOT1 Like Histone Lysine Methyltransferase)
|
CDH1 expression • VIM expression
4d
Characterization of Epithelial-Mesenchymal and Neuroendocrine Differentiation States in Pancreatic and Small Cell Ovarian Tumor Cells and Their Modulation by TGF-β1 and BMP-7. (PubMed, Cells)
Likewise, in BIN-67 cells, BMP-7 was able to reduce proliferation, while in SCCOHT-1 cells this occurred only upon combined treatment with TGF-β and BMP-7. We conclude that in PDAC-derived tumor cells, NED is closely linked to EMT and TGF-β signaling, which may have implications for the therapeutic use of TGF-β inhibitors in PDAC management.
Journal • Tumor cell
|
CDH1 (Cadherin 1) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • SSTR5 (Somatostatin Receptor 5) • SNAI1 (Snail Family Transcriptional Repressor 1) • SYP (Synaptophysin) • CHGA (Chromogranin A) • SMAD2 (SMAD Family Member 2) • SMAD3 (SMAD Family Member 3)
|
CDH1 expression • VIM expression
5d
Exploring the molecular mechanism of Taohong Siwu decoction in the treatment of non-small-cell lung cancer based on network pharmacology and molecular docking. (PubMed, J Pharm Pharmacol)
The potential targets and molecular mechanisms of THSWD in the treatment of NSCLC were preliminarily revealed by a comprehensive analysis in this study, which will provide new ideas and methods for the study of the mechanism of traditional Chinese medicine in treating lung cancer.
Journal
|
EGFR (Epidermal growth factor receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • MAP1LC3A (Microtubule Associated Protein 1 Light Chain 3 Alpha) • MAPK8 (Mitogen-activated protein kinase 8)
|
CCND1 expression • CDH1 expression • IL6 expression
5d
METTL3-Mediated m6A Methylation of USP21 Contributes to Hepatocellular Carcinoma Progression by Stabilizing H2BFS Through Deubiquitination. (PubMed, Biochem Genet)
Further, METTL3-mediated m6A methylation of USP21. METTL3-mediated m6A methylation of USP21 promoted HCC progression by stabilizing H2BFS through deubiquitination.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • METTL3 (Methyltransferase Like 3)
|
CDH1 expression • VIM expression
5d
Human umbilical cord mesenchymal stem cells derived-exosomes alleviate LPS-induced cervical inflammation and epithelial-mesenchymal transition. (PubMed, Am J Transl Res)
Our results support that hucMSC-Ex alleviates LPS-induced cervical inflammation, possibly by inhibition of EMT.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • IL10 (Interleukin 10) • CDH2 (Cadherin 2) • PCNA (Proliferating cell nuclear antigen) • IL1B (Interleukin 1, beta)
|
CDH1 expression
5d
High mobility group protein N2 inhibits the progression of hepatocellular carcinoma and the related molecular mechanisms. (PubMed, Cytotechnology)
HMGN2 expression was significantly decreased in patients with HCC. HMGN2 inhibits the malignant behavior of HCC cells and is a potential therapeutic target for HCC.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen)
|
CDH1 expression
9d
Lymphovascular Tumoral Emboli in Inflammatory Breast Cancer Result from Haptotaxis-Mediated Encircling Lymphangiogenesis. (PubMed, Lymphatics)
Multicolor murine imaging studies indicated that reporter-labeled stroma initially encircled clumps of tumor cells and then served as a scaffold that supported nestin-GFP-labeled endothelial haptotaxis resulting in encircling lymphangiogenesis, confirmed by dual LYVE1 immunofluorescence. The present studies demonstrate a possible mechanism of a critical step of the tumor emboli formation of IBC.
Journal
|
CDH1 (Cadherin 1) • VEGFC (Vascular Endothelial Growth Factor C) • NES (Nestin) • LYVE1 (Lymphatic vessel endothelial hyaluronan receptor 1)
|
CDH1 expression
10d
MiR-592 Attenuates Tamoxifen Resistance in Breast Cancer Through PIK3CA-Mediated PI3K/AKT/mTOR Signaling Pathway. (PubMed, Appl Biochem Biotechnol)
PIK3CA overexpression partially reversed these reductions. In conclusion, our study demonstrates that miR-592 attenuates TAM resistance by inhibiting the PIK3CA-driven PI3K/AKT/mTOR signaling pathway, representing a promising strategy to address chemoresistance in BC.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDH1 (Cadherin 1) • CASP3 (Caspase 3)
|
CDH1 expression • PIK3CA expression • PIK3CA overexpression
|
tamoxifen
11d
Modified Jiaoqi Powder enhances epithelial autophagy against TNF-triggered apoptosis in chronic ulcerative colitis. (PubMed, Phytomedicine)
These results provide novel therapeutic strategies indicating that MJQP may be a promising candidate treatment for chronic UC by promoting epithelial barrier restitution by enhancing epithelial autophagy against TNF-mediated apoptosis.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
|
CDH1 expression
13d
Exploration of Novel Metabolic Features Reflecting Statin Sensitivity in Lung Cancer Cells. (PubMed, Biol Pharm Bull)
Our data suggest that the cholesterol synthetic flow and CoA content may be limited in statin-sensitive cancer cells. We also suggest that CoA synthesis and cholesterol storage may fluctuate with atorvastatin treatment in statin-sensitive cancer cells.
Journal
|
CDH1 (Cadherin 1) • ANK2 (Ankyrin 2)
|
CDH1 expression
|
atorvastatin
14d
Nimbolide attenuates hepatocellular carcinoma by regulating miRNAs 21, 145 and 221 and their target gene expression. (PubMed, Gene)
We identified for the first time that nibmolide treatment to HCC mice significantly attenuated hepatic miRNAs 21 & 221 expressions and sheltered miR-145 expression. These findings were further confirmed with in-silico studies. Moreover, nibmolide treatment in HCC mice regulates miRNA target genes involved in cancer cell proliferation and inflammation, thereby attenuating HCC progression in mice.
Journal
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • MIR221 (MicroRNA 221) • MMP9 (Matrix metallopeptidase 9) • CLDN2 (Claudin 2) • MIR145 (MicroRNA 145)
|
CCND1 expression • CDH1 expression
15d
Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer. (PubMed, JCO Precis Oncol)
We demonstrate in our exploratory study that biomarkers involved in the process of EMT could have a prognostic impact in a cohort of patients with BC uniformly treated and with long-term follow-up. Genes known to be involved in EMT were associated with improved eribulin efficacy, while suggesting a poorer outcome with CDK4/6i.
Journal • Metastases
|
PTEN (Phosphatase and tensin homolog) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • CDH2 (Cadherin 2) • TWIST1 (Twist Family BHLH Transcription Factor 1) • SNAI1 (Snail Family Transcriptional Repressor 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
CDH1 expression • SMAD4 expression • ZEB1 expression
|
Halaven (eribulin mesylate)
15d
Identifying the signature of NAD+ metabolism-related genes for immunotherapy of gastric cancer. (PubMed, Heliyon)
This study unveils a novel NMRGs-related gene signature, highlighting APOD as a prognostic biomarker linked to the tumor microenvironment. APOD drives GC cell proliferation and metastasis through the Wnt/β-catenin/EMT signaling pathway, establishing it as a promising therapeutic target for GC patients.
Journal • IO biomarker
|
CDH1 (Cadherin 1) • CDH2 (Cadherin 2)
|
CDH1 expression
16d
Exosomal miR-20b-5p Induces EMT and Enhances Progression in Non-Small Cell Lung Cancer Via TGFBR2 Downregulation. (PubMed, J Biochem Mol Toxicol)
In vitro and in vivo, exosomes with high levels of miR-20b-5p were linked to the progression of NSCLC. Our data suggest that exosomes with high levels of miR-20b-5p can increase development and metastasis of NSCLC cells by downregulating TGFBR2, which would serve as a predictive and diagnostic marker for NSCLC.
Journal
|
CDH1 (Cadherin 1) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • VIM (Vimentin) • MIR20B (MicroRNA 20b)
|
CDH1 expression • VIM expression • miR-20b-5p expression
18d
SDC1 Influences Keloid Fibroblasts Migration and Invasion via Targeting Wnt/β-Catenin Signaling Pathway Mediated EMT. (PubMed, J Craniofac Surg)
The results showed that the knockdown of SDC1 markedly suppressed the migration and invasion abilities of keloid fibroblasts and reduced the phenotypes of EMT by inhibiting Wnt/β-catenin signaling pathway. The authors' findings suggest that SDC1 may influences keloid fibroblasts migration and invasion through targeting Wnt/β-catenin signaling pathway mediated EMT, which supports its potential value as a therapeutic target for the treatment of keloid.
Journal
|
CDH1 (Cadherin 1) • SDC1 (Syndecan 1) • VIM (Vimentin) • CDH2 (Cadherin 2)
|
CDH1 expression • VIM expression
19d
Oct4 promotes the progression and radioresistance of esophageal squamous cell carcinoma by regulating epithelial-mesenchymal transition (PubMed, Zhonghua Zhong Liu Za Zhi)
The radiosensitivity was enhanced, with the radiosensitivity enhancement ratio being 1.37±0.11 vs 1.00±0.01 (P=0.037), and after radiotherapy the expression of γ-H2AX increased. Oct4 is involved in the regulation of epithelial-mesenchymal transformation of esophageal squamous cell carcinoma, which promotes the proliferation, migration, and radioresistance of esophageal squamous cell carcinoma.
Journal
|
CDH1 (Cadherin 1) • POU5F1 (POU Class 5 Homeobox 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • H2AX (H2A.X Variant Histone) • TCF4 (Transcription Factor 4)
|
CDH1 expression • VIM expression • ZEB1 expression • POU5F1 expression
19d
Exosome-based strategy against colon cancer using small interfering RNA-loaded vesicles targeting soluble a proliferation-inducing ligand. (PubMed, World J Stem Cells)
The use of bioengineered Exs targeting sAPRIL and containing siPIN1 demonstrated superior efficacy in inhibiting tumor growth and epithelial-mesenchymal transition, highlighting their potential as a therapeutic strategy for colon cancer.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin)
|
CDH1 expression
19d
Anthracosis, epidemiology, gene and cancer: An updated mini-review. (PubMed, Caspian J Intern Med)
Finally, this article discussed the relationship between anthracosis and cancers. According to the studied literature, antracotic people are more susceptible to pulmonary adenocarcinoma, hepatic nodules, renal cell carcinoma, and esophageal cancer.
Review • Journal
|
CDH1 (Cadherin 1) • RASSF1 (Ras Association Domain Family Member 1)
|
TP53 mutation • CDH1 expression
20d
Tissue Cadherin 17 (CDH17): An Important Prognostic Determinant of Colorectal Cancer Using Digital Image Analysis. (PubMed, Cancer Rep (Hoboken))
Increased CDH17 M Score was associated with advanced tumor staging and poor survival outcomes using an automated IHC system integrated with a digital image analysis software, highlighting CDH17 could serve as an independent prognostic marker for CRC patients.
Retrospective data • Journal
|
CDH17 (Cadherin 17)
|
CDH1 expression
20d
Nanaomycin K Inhibited Cell Proliferation and Epithelial-Mesenchymal Transition in Renal Cell Carcinoma. (PubMed, Biol Pharm Bull)
Intratumor administration of nanaomycin K significantly inhibited tumor growth without apparent adverse events for mice. These results indicate that nanaomycin K inhibit cell growth and EMT in TGF-β-induced advanced RCC, and that nanaomycin K is a potential candidate for the treatment of RCC.
Journal
|
CDH1 (Cadherin 1) • CASP3 (Caspase 3) • VIM (Vimentin) • CASP8 (Caspase 8) • TGFB1 (Transforming Growth Factor Beta 1) • CASP9 (Caspase 9) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
CDH1 expression • VIM expression
22d
Promoter hypermethylation-mediated downregulation of PAX6 promotes tumor growth and metastasis during the progression of liver cancer. (PubMed, Clin Epigenetics)
PAX6 functions as a tumor suppressor partly through upregulation of CDH1 and downregulation of THBS1. Promoter hypermethylation-mediated suppression of PAX6 reduces the tumor suppressor function in the progression of liver cancer.
Journal
|
CDH1 (Cadherin 1)
|
CDH1 expression • THBS1 overexpression
22d
Downregulation of lncRNA-MALAT1, Altered Immunohistochemical Expression of Cyclin D1 Protein and E-Cadherin Protein in Correlation to Meningioma Grades. (PubMed, Asian Pac J Cancer Prev)
lncRNA MALAT1 is downregulated in meningiomas and associated with increased aggressiveness. Overexpressed cyclin D1 and decreased E-cadherin expression are also associated with high grade meningioma.
Journal
|
CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1)
|
CCND1 overexpression • CCND1 expression • CDH1 expression
23d
Effect of silencing Ras homolog family member C on proliferation, invasion, and migration of salivary adenoid cystic carcinoma. (PubMed, Hua Xi Kou Qiang Yi Xue Za Zhi)
RhoC is highly expressed in SACC, and RhoC silencing may target the downstream ROCK1/p38MAPK/TWIST1 signaling pathway, thereby inhibiting the proliferation, invasion, migration, and EMT of SACC while promoting its apoptosis. On the contrary, miR-138-5p is lowly expressed in SACC and is a potential upstream gene of RhoC, and there may be binding sites between the two genes.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • TWIST1 (Twist Family BHLH Transcription Factor 1) • MIR138 (MicroRNA 138) • ROCK1 (Rho Associated Coiled-Coil Containing Protein Kinase 1)
|
CDH1 expression • VIM expression
23d
Polyribonucleotide phosphorylase is overexpressed in hepatocellular cancer, promoting epithelial phenotype maintenance and tumor progression. (PubMed, Pathol Res Pract)
In HCC tissues, PNPT1 expression was linked to markers of epithelial phenotype, oxidative stress, and poor prognosis, especially in non-viral HCC cases. These findings suggest that PNPase may play a crucial role in the progression of well-differentiated HCC tumors, serving as a poor prognostic biomarker.
Journal
|
CDH1 (Cadherin 1)
|
CDH1 expression
23d
Vascular endothelial growth factor facilitates the effects of telocytes on tumor cell proliferation and migration. (PubMed, Front Cell Dev Biol)
Notably, these effects were inhibited by the addition of bevacizumab. In conclusion, our findings illuminated the role of telocytes in promoting tumor progression, and confirmed their crucial regulatory role in the growth of tumor cells.
Journal • Tumor cell
|
VEGFA (Vascular endothelial growth factor A) • CDH1 (Cadherin 1) • VIM (Vimentin)
|
CDH1 expression • VIM expression
|
Avastin (bevacizumab)
24d
Metformin alleviates colitis-associated colorectal cancer via inhibition of the TLR4/MyD88/NFκB/MAPK pathway and macrophage M2 polarization. (PubMed, Int Immunopharmacol)
Metformin inhibited colorectal tumorigenesis by suppressing the TLR4/MyD88/NFκB/MAPK pathway, modulating macrophage M2 polarization and increasing SCFA levels. It holds promise as a potentially effective treatment for colorectal cancer.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CDH1 (Cadherin 1) • TLR4 (Toll Like Receptor 4) • CLDN1 (Claudin 1) • MRC1 (Mannose Receptor C-Type 1) • MUC2 (Mucin 2) • TJP1 (Tight Junction Protein 1) • OCLN (Occludin)
|
CDH1 expression
|
metformin
24d
Targeted Delivery of Celastrol by GA-Modified Liposomal Calcium Carbonate Nanoparticles to Enhance Antitumor Efficacy Against Breast Cancer. (PubMed, Pharmaceutics)
GA-LCC-CEL nanoparticles represent a promising targeted drug delivery approach for breast cancer, enhancing CEL's antitumor efficacy and potentially inhibiting cancer progression by modulating EMT-related proteins.
Journal
|
CDH1 (Cadherin 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • ANXA5 (Annexin A5)
|
CDH1 expression • ZEB1 expression
24d
Serum from Hypertensive Patients Induces Cancer-Supporting Phenotype of Vascular Endothelium In Vitro. (PubMed, Biomolecules)
Our report shows that hypertension may potentiate cancer cell aggressiveness by modulating endothelial cell phenotype. Further tests with antihypertensive drugs are required to assess whether effective treatment of hypertension can mitigate its cancer-promoting potential.
Preclinical • Journal
|
IL6 (Interleukin 6) • CDH1 (Cadherin 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL2 (Chemokine (C-C motif) ligand 2) • TGFB1 (Transforming Growth Factor Beta 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
|
CDH1 expression
26d
Long non-coding RNA HOTAIR promotes tumorigenesis by affecting proliferation, invasion, migration and apoptosis of liver cancer cells. (PubMed, Folia Histochem Cytobiol)
In this study, we proposed a novel mechanism in which HOTAIR promotes invasion and migration of liver cancer cells by regulating the nuclear localization of Snail2.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • HOTAIR (HOX Transcript Antisense RNA) • MMP9 (Matrix metallopeptidase 9) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
CDH1 expression
26d
Oxaliplatin and 5-fluorouracil promote epithelial-mesenchymal transition via activation of KRAS/ERK/NF-κB pathway in KRAS-mutated colon cancer cells. (PubMed, Mol Cell Biochem)
Combined administration with KRAS siRNA, MEK1/2 inhibitor trametinib, and NF-κB inhibitor dimethyl fumarate (DMF), suppressed L-OHP- and 5-FU-induced EMT. These results suggest that KRAS/ERK/NF-κB pathway activation is important for EMT induction by L-OHP and 5-FU treatment. Thus, MEK1/2 and NF-κB inhibitors may facilitate the resistance acquisition to L-OHP and 5-FU therapy in KRAS G13D-mutated colon cancer.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
KRAS mutation • KRAS wild-type • KRAS G13D • RAS wild-type • KRAS G13 • CDH1 expression
|
Mekinist (trametinib) • 5-fluorouracil • oxaliplatin
26d
Polyamine-modified naphthalimide derivative 9C inhibits colorectal cancer through ROS-mediated ER stress, migration and invasion. (PubMed, Toxicol In Vitro)
Pretreatment of ER stress inhibitor, such as salubrinal, and autophagy inhibitor, such as 3-methyladenine (3-MA), partially reversed 9C-induced inhibition of cell growth...Removal of ROS using N-acetyl-L-cysteine (NAC) attenuated the expression of ATF4, CHOP, death receptors, E-cadherin, and the apoptosis and autophagy related proteins. Taken together, our results suggested that ROS-mediated ER stress, migration, and invasion is responsible for the therapeutic potential of naphthalimides including 9C in CRC.
Journal
|
CDH1 (Cadherin 1) • ATF4 (Activating Transcription Factor 4)
|
CDH1 expression
|
salubrinal
27d
FMNL3 Promotes Migration and Invasion of Breast Cancer Cells via Inhibiting Rad23B-Induced Ubiquitination of Twist1. (PubMed, J Cell Physiol)
Furthermore, Twist1 could directly bind to the fmnl3 promoter to facilitate FMNL3 transcription. To conclude, this study indicated that FMNL3 acted as a pro-metastasis factor in breast cancer by promoting Twist1 stability to suppress CDH1 transcription.
Journal
|
CDH1 (Cadherin 1) • TWIST1 (Twist Family BHLH Transcription Factor 1) • RAD23B (RAD23 Homolog B)
|
CDH1 expression
29d
Inhibition of miR-20a-5p Suppresses Epithelial-Mesenchymal Transition of Colorectal Cancer Cells Through GJA1. (PubMed, Mol Biotechnol)
miR-20a-5p inhibitor + sh-GJA1 promoted the invasion, migration, and proliferation of colon cancer cells and EMT process. Overall, miR-20a-5p could target GJA1 to down-regulate the GJA1 expression, thereby regulating the EMT response, and ultimately promoting the progression of colorectal cancer.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • GJA1 (Gap Junction Protein Alpha 1) • MIR20A (MicroRNA 20a)
|
CDH1 expression • VIM expression • GJA1 expression
29d
Relevance of the Immunohistochemical Expression of p53 and E-cadherin in the Grading of Urothelial Carcinoma: A Single-Center Cross-Sectional Observational Study. (PubMed, Cureus)
Conclusion Considering that elevated p53 protein expression is linked to aggressive tumor behavior, a more intensive treatment strategy is recommended for patients with non-muscle-invasive bladder cancer (NMIBC) who show high p53 protein scores. On the other hand, the downregulation or absence of E-cadherin expression has been recognized as a strong indicator of advanced grade and higher clinical stages.
Observational data • Journal
|
TP53 (Tumor protein P53) • CDH1 (Cadherin 1)
|
TP53 expression • TP53 overexpression • CDH1 expression
1m
Altingia chinensis petroleum ether extract suppresses NSCLC via induction of apoptosis, attenuation of EMT, and downregulation of PI3K/Akt pathway. (PubMed, Phytomedicine)
Overall, APE exhibits anti-tumor effects on NSCLC via induction of apoptosis, attenuation of EMT, and its mechanism involves the suppression of the PI3K/Akt pathway. Our study offers new insights for the identification of novel drug development for NSCLC.
Journal • IO biomarker
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • VIM (Vimentin) • ANXA5 (Annexin A5)
|
CDH1 expression • VIM expression
1m
Ginsenoside Rg3 attenuates the stemness of breast cancer stem cells by activating the hippo signaling pathway. (PubMed, Toxicol Appl Pharmacol)
Mechanistically, Rg3 attenuates the stemness of BCSCs by activating the Hippo signaling pathway. This study provides a comprehensive evaluation of Rg3 as a promising therapeutic agent against BCSCs.
Journal • Cancer stem • IO biomarker
|
EGFR (Epidermal growth factor receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • CDH1 (Cadherin 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • SOX2 • CD24 (CD24 Molecule) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • NANOG (Nanog Homeobox) • SIRT1 (Sirtuin 1)
|
MYC expression • CDH1 expression
1m
Imatinib Impedes EMT and Notch Signalling by Inhibiting p300 Acetyltransferase in Breast Cancer Cells. (PubMed, Mol Carcinog)
These results highlight the ability of Imatinib to suppress EMT through modulation of the Notch signalling pathway, offering a novel therapeutic avenue for breast cancer treatment. Overall, Imatinib demonstrates considerable potential for repurposing in breast cancer management by targeting critical oncogenic pathways involved in EMT and cancer progression.
Journal
|
CDH1 (Cadherin 1) • FN1 (Fibronectin 1) • HES1 (Hes Family BHLH Transcription Factor 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
CDH1 expression
|
imatinib
1m
miRNA-199b-5p suppresses of oral squamous cell carcinoma by targeting apical-basolateral polarity via Scribble/Lgl. (PubMed, Mol Ther Nucleic Acids)
The disruption of Scribble localization under hypoxic conditions, but its localization was maintained in miR-199b-5p oral squamous cell carcinoma cell lines and in vivo. These results suggest that Scribble functions as a tumor suppressor marker mediated by miR-199b-5p in oral squamous cell carcinoma.
Journal
|
CDH1 (Cadherin 1) • MIR199B (MicroRNA 199b)
|
CDH1 expression
1m
Enhancing lung cancer growth inhibition with calcium ions: Role of mid- and high-frequency electric field pulses. (PubMed, Biomed Pharmacother)
The study provides insights into the modulation of key cellular processes, indicating that nsPEF technology could improve the outcomes of conventional cancer treatments through enhanced efficacy and potentially mitigating drug resistance mechanisms. The promising results advocate for further research to optimize nsPEF protocols for clinical application, highlighting the potential of electrical fields in advancing cancer therapy.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • CDH2 (Cadherin 2)
|
CDH1 expression